Huakang Biomedical Holdings Co (HKSE:08622) Change In Receivables : HK$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Huakang Biomedical Holdings Co Change In Receivables?

Huakang Biomedical Holdings Co's change in receivables for the quarter that ended in Dec. 2024 was HK$0.00 Mil. It means Huakang Biomedical Holdings Co's Accounts Receivable stayed the same from Jun. 2024 to Dec. 2024 .

Huakang Biomedical Holdings Co's change in receivables for the fiscal year that ended in Dec. 2024 was HK$-0.42 Mil. It means Huakang Biomedical Holdings Co's Accounts Receivable increased by HK$0.42 Mil from Dec. 2023 to Dec. 2024 .

Huakang Biomedical Holdings Co's Accounts Receivable for the quarter that ended in Dec. 2024 was HK$10.62 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Huakang Biomedical Holdings Co's liquidation value for the three months ended in Dec. 2024 was HK$36.45 Mil.

Huakang Biomedical Holdings Co Change In Receivables Historical Data

The historical data trend for Huakang Biomedical Holdings Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huakang Biomedical Holdings Co Change In Receivables Chart

Huakang Biomedical Holdings Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-3.68

0.51

-0.16

0.07

-0.42

Huakang Biomedical Holdings Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Huakang Biomedical Holdings Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

Huakang Biomedical Holdings Co (HKSE:08622) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Huakang Biomedical Holdings Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	10.622	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Huakang Biomedical Holdings Co's accounts receivable are only considered to be worth 75% of book value:

Huakang Biomedical Holdings Co's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	38.965	-	11.93	+	0.75 * 10.622	+	0.5 * 2.901
=	36.45

Huakang Biomedical Holdings Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Huakang Biomedical Holdings Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Huakang Biomedical Holdings Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huakang Biomedical Holdings Co Ltd (HKSE:08622) » Definitions » Change In Receivables

Traded in Other Exchanges

N/A

Address

No.16 Yinkui Road, 1-3 floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN

Website

http://www.szhuakang.com

Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents; EBV antibody detection reagents; and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and overseas.

Executives

Yu Chi Mau	2106 Person having a security interest in shares
Li King Yeung	2106 Person having a security interest in shares
Crystal Grant Limited	2101 Beneficial owner
Arena Investment Management (singapore) Pte Ltd	2102 Investment manager
Arena Investors, Lp	2102 Investment manager
Arena Sg Spv I, Llc	2201 Interest of corporation controlled by you
Tgga, Llc	2106 Person having a security interest in shares
Lau Lai Yee	2201 Interest of corporation controlled by you
Kokusai Resources Company Limited	2101 Beneficial owner
Zhang Shuguang	2101 Beneficial owner
Chang Yim Yang	2401 A concert party to an agreement to buy shares
Ever Charming Inc.	2101 Beneficial owner
Wealthy Pride Investment Limited	2101 Beneficial owner

Huakang Biomedical Holdings Co Headlines

No Headlines